D. E. Shaw & Co., Inc. Viracta Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $59,949 - $127,963	-26,883 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $31,607 - $74,187	-9,379 Reduced 25.86%	26,883 $98,000
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $284,294 - $454,362	36,262 New	36,262 $291,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.